HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM DOJOLVI™

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
		-=
DOB:	Gender:	Physician:
565.	Genden	i nysician.
Office Phone:	Office Fax:	Office Contact:
office i fiolie.	office rax.	omee contact.

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Product being requested: □ Dojolvi[™] (triheptanoin)

Dosing/Frequency:_

If the request is for reauthorization, proceed to reauthorization section.				
Questions	Yes	No	Comments/Notes	
1. Is the therapy prescribed by, or in consultation with, a				
metabolic disease specialist or a physician who specializes in				
the management of long-chain fatty acid oxidation disorders?				
2. Does the member have a molecularly confirmed diagnosis of a			Please provide documentation	
long-chain fatty acid oxidation disorder based on 2 of the				
following:				
 Disease-specific acylcarnitine elevations on a newborn 				
blood spot or in plasma				
 Enzyme activity assay (in cultured fibroblasts or 				
lymphocytes) below the lower limit of normal				
 Genetic testing demonstrating pathogenic mutations in a 				
gene associated long-chain fatty acid oxidation disorders				
3. Is the member receiving disease related dietary management?			Please provide documentation	
REAUTHORIZATION				
 Is the request for reauthorization of therapy? 				
2. Does updated clinical documentation show disease progression			Please provide documentation	
or toxicity to therapy?				
What medications and/or treatment modalities have been tried in the past for this condition? Please document				
name of treatment, reason for failure, treatment dates, etc.				

Physician Signature:

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy PHARM-HU-112 Origination Date: 01/01/2022 Reviewed/Revised Date: 01/18/2023 Next Review Date: 01/18/2024 Current Effective Date: 02/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.